| Systematic (IUPAC) name | |
|---|---|
| 1-(6-methyl-1,3-benzodioxol-5-yl)propan-2-amine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries) |
| Routes | Oral |
| Identifiers | |
| ATC code | None |
| PubChem | CID 10511982 |
| ChemSpider | 8687383 |
| ChEMBL | CHEMBL6376 |
| Chemical data | |
| Formula | C11NO2 |
| Mol. mass | 193.24 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
6-Methyl-3,4-methylenedioxyamphetamine (6-Methyl-MDA) is an entactogen and psychedelic drug of the amphetamine class.[1] It was first synthesized in the late 1990s by a team including David E. Nichols at Purdue University while investigating derivatives of MDA and MDMA.[1]
6-Methyl-MDA has IC50 values of 783nM, 28,300nM, and 4,602nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine in rat synaptosomes.[1] In animal studies it substitutes for MBDB, MMAI, LSD, and DOI, though not amphetamine, but only partially and at high doses.[1] Thus, while several-fold less potent than its analogues 2-methyl-MDA and 5-methyl-MDA, and approximately half as potent as MDA, 6-methyl-MDA is still significantly active,[1] and appropriate doses may be similar to or somewhat higher than those of MDMA.[citation needed]
|
||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)